Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $188.75 Million

Brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will post sales of $188.75 million for the current quarter, Zacks reports. Six analysts have provided estimates for Myriad Genetics’ earnings. The highest sales estimate is $189.93 million and the lowest is $188.00 million. Myriad Genetics posted sales of $196.50 million in the same quarter last year, which suggests a negative year-over-year growth rate of 3.9%. The firm is scheduled to issue its next earnings report on Tuesday, February 6th.

On average, analysts expect that Myriad Genetics will report full-year sales of $188.75 million for the current financial year, with estimates ranging from $758.90 million to $782.01 million. For the next fiscal year, analysts anticipate that the company will post sales of $806.00 million per share, with estimates ranging from $769.32 million to $842.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. During the same period last year, the company earned $0.23 EPS. Myriad Genetics’s revenue for the quarter was up 7.2% compared to the same quarter last year.

A number of research analysts have recently commented on the company. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. ValuEngine upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Friday, November 10th. Barclays PLC lowered their price objective on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 9th. Zacks Investment Research cut Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $23.00 price objective (up previously from $21.00) on shares of Myriad Genetics in a research note on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $28.10.

COPYRIGHT VIOLATION NOTICE: This report was published by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://weekherald.com/2017/11/17/brokerages-expect-myriad-genetics-inc-mygn-will-announce-quarterly-sales-of-188-75-million.html.

In related news, insider Alexander Ford sold 3,031 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John T. Henderson sold 30,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the transaction, the director now directly owns 52,524 shares in the company, valued at approximately $1,591,477.20. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. GHP Investment Advisors Inc. lifted its holdings in shares of Myriad Genetics by 11.1% during the 3rd quarter. GHP Investment Advisors Inc. now owns 48,710 shares of the company’s stock valued at $1,762,000 after purchasing an additional 4,853 shares during the last quarter. Vanguard Group Inc. grew its position in Myriad Genetics by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock worth $162,992,000 after purchasing an additional 56,708 shares during the period. Airain ltd acquired a new stake in Myriad Genetics during the 2nd quarter worth about $1,097,000. PDT Partners LLC acquired a new stake in Myriad Genetics during the 2nd quarter worth about $8,481,000. Finally, Blair William & Co. IL acquired a new stake in Myriad Genetics during the 2nd quarter worth about $1,048,000.

Myriad Genetics (MYGN) traded down $0.53 during midday trading on Friday, reaching $32.88. The company’s stock had a trading volume of 956,880 shares, compared to its average volume of 1,221,158. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $37.30. The company has a current ratio of 2.34, a quick ratio of 2.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $2,280.00, a PE ratio of 28.67, a P/E/G ratio of 1.98 and a beta of 0.24.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply